Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
OPK Price Action
Last 7 days
-2.1%
Last 30 days
-17.6%
Last 90 days
-6.7%
Trailing 12 Months
12.9%
OPK Stock Price
OPK RSI Chart
OPK Valuation
OPK Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
OPK Fundamentals
OPK Revenue
OPK Earnings
OPK Profitability
OPK Investor Care
OPK Alerts
Revenue & Growth
Revenue Breakdown
As of: Dec 31, 2024
Total
| |||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2024 | 799.6M | 716.4M | 711.4M | 713.1M |
| 2023 | 912.6M | 868.1M | 866.9M | 863.5M |
| 2022 | 1.6B | 1.4B | 1.2B | 1.0B |
| 2021 | 1.8B | 1.9B | 1.9B | 1.8B |
| 2020 | 891.0M | 965.8M | 1.2B | 1.4B |
| 2019 | 957.8M | 920.5M | 899.4M | 901.9M |
| 2018 | 954.5M | 925.6M | 929.4M | 990.3M |
| 2017 | 1.1B | 1.1B | 1.1B | 966.0M |
| 2016 | 730.6M | 1.0B | 1.1B | 1.1B |
| 2015 | 98.9M | 117.8M | 241.1M | 491.7M |
| 2014 | 87.4M | 87.2M | 86.3M | 91.1M |
| 2013 | 69.6M | 83.3M | 92.1M | 96.5M |
| 2012 | 29.8M | 31.6M | 36.6M | 47.0M |
| 2011 | 32.3M | 33.3M | 34.4M | 28.0M |
| 2010 | 0 | 12.4M | 20.5M | 28.5M |
| 2009 | 0 | 0 | 0 | 4.4M |
Get all data in R, Python etc through our Historical Stock Data APIs
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
| CEO | Dr. Phillip Frost Ph.D. |
|---|---|
| WEBSITE | opko.com |
| SECTOR | Healthcare |
| INDUSTRY | Diagnostics & Research |
| EMPLOYEES | 4196 |
